Conventional heparin and semisynthetic heparin analogue (SSHA) alteration of blood coagulation after embolic occlusion of human renal circulation

Thrombosis Research
S TörngrenC R Nyman

Abstract

Blood coagulation and fibrinolytic variables were measured in a peripheral vein in a study of 21 consecutive patients before and after angio-embolization of renal carcinoma. The first ten patients received conventional heparin, 5000 IU twice daily, and the following eleven a semi-synthetic heparin analogue (SSHA), 50 mg twice daily, for 5 days. The first injection was given 2 hours before embolization and the last injection at least 12 hours before the last blood sampling. Both groups showed increased levels of FPA on day 5-7, indicating that the anticoagulant influence had ceased. F VII levels decreased only in the SSHA group from embolization to day 3, but were increased in both groups on day 5-7. Levels of thrombin-antithrombin complexes (TAT) were significantly increased in the heparin group 2 hours after embolization, indicating that thrombin activity had been formed. The corresponding TAT level in the SSHA group was not significantly increased. The differences could possibly indicate a different mechanism of action on blood coagulation of SSHA as compared with heparin, with involvement of extrinsic pathway and maybe by-passing antithrombin III inhibition.

References

Jan 15, 1977·Lancet·D P ThomasV V Kakkar
Oct 1, 1977·European Journal of Clinical Investigation·D CollenM Verstraete
Jan 1, 1987·Haemostasis·O R OdegaardT R Andersson
Jan 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·C B Laurell
Sep 15, 1983·Thrombosis Research·D B RylattA J Webber
Jan 1, 1951·Acta Haematologica·F KOLLERF DUCKERT

❮ Previous
Next ❯

Citations

Jul 21, 1999·Nature Neuroscience·P Mombaerts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.